Tepotinib Hydrochloride Patent Expiration
Tepotinib Hydrochloride is Used for treating solid tumors with MET kinase alterations, including lung cancer, by administering Tepotinib. It was first introduced by Emd Serono Inc
Tepotinib Hydrochloride Patents
Given below is the list of patents protecting Tepotinib Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tepmetko | US8580781 | Pyridazinone derivatives | Mar 19, 2030 | Emd Serono Inc |
| Tepmetko | US8329692 | Pyrimidinyl pyridazinone derivatives | Oct 30, 2029 | Emd Serono Inc |
| Tepmetko | US8927540 | Pyridazinone derivatives | Jul 21, 2028 | Emd Serono Inc |
| Tepmetko | US8658643 | Pyrimidinyl pyridazinone derivatives | Jul 04, 2028 | Emd Serono Inc |
| Tepmetko | US9062029 | Pyrimidinyl pyridazinone derivatives | Jul 04, 2028 | Emd Serono Inc |
| Tepmetko | US9403799 | Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase | Jul 04, 2028 | Emd Serono Inc |
| Tepmetko | US8921357 | Pyridazinone derivatives | May 30, 2028 | Emd Serono Inc |
| Tepmetko | US9284300 | Pyridazinone derivatives | Apr 29, 2028 | Emd Serono Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Tepotinib Hydrochloride's patents.
Latest Legal Activities on Tepotinib Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Tepotinib Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 29 May, 2024 | US8329692 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 Jan, 2024 | US9403799 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 30 Aug, 2023 | US9284300 |
| Second letter to regulating agency to determine regulatory review period | 27 Feb, 2023 | US8580781 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 07 Dec, 2022 | US9062029 |
| Letter from FDA or Dept of Agriculture re PTE application | 21 Sep, 2022 | US8580781 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 Jun, 2022 | US8927540 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 15 Jun, 2022 | US8921357 |
| Initial letter Re: PTE Application to regulating agency | 25 Feb, 2022 | US8580781 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 Aug, 2021 | US8658643 |
Tepotinib Hydrochloride's Family Patents
